Exploring miRNA based approaches in cancer diagnostics and therapeutics

Critical Reviews in Oncology/Hematology

Volumn 98, Issue , 2016, Pages 12-23

  Mishra, Shivangi ^a   Yadav, Tanuja ^a   Rani, Vibha ^a  

^a JAYPEE INSTITUTE OF INFORMATION TECHNOLOGY   (India)

Author keywords

Cancer; MicroRNAs; Oncogenes; Patents; Therapeutics; Tumor suppressors

Indexed keywords

LET 7 PROTEIN; MICRORNA; MICRORNA 142; MICRORNA 15; MICRORNA 155; MICRORNA 16; MICRORNA 206; MICRORNA 21; MICRORNA 34; MICRORNA 92; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER DIAGNOSIS; CANCER RESEARCH; CANCER THERAPY; CARCINOGENESIS; COLORECTAL CANCER; DRUG DELIVERY SYSTEM; DRUG TARGETING; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; ONCOGENE; PANCREAS CANCER; PROSTATE CANCER; REVIEW; SOFT TISSUE SARCOMA; THYROID CANCER; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; NEOPLASMS; PATHOLOGY; PHYSIOLOGY;

CARCINOGENESIS; HUMANS; MICRORNAS; NEOPLASMS; ONCOGENES;

EID: 84957430324     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.10.003     Document Type: Review

References (89)

1. Andreas, G.B., Mike, B., Charles, D.J., et al., 2009. miR-34 Regulated Genes and Pathways as Targets for Therapeutic Intervention. US 20090227533.
2. Andreas, G.B., Mike, B., Charles, D.J., David, B., 2009. mir-21 regulated genes and pathways as targets for therapeutic intervention. US 20090192102.
3. Aqeilan R.I., Calin G.A., Croce C.M. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ. 2010, 17:215-220.
4. Asuragen, Inc., 2010. Compositions and methods related to mir-16 and therapy of prostate cancer. WO 2009154835.
5. Asuragen, Inc., 2009. mir-15, mir-26, mir-31, mir-145, mir-147,mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3P regulated genes and pathways as targets for therapeutic intervention. US 20090131356.
6. Ben-Shushan D., Markovsky E., Gibori H., Tiram G., Scomparin A., Satchi-Fainaro R. Overcoming obstacles in microRNA delivery towards improved cancer therapy. Drug Delivery Transl. Res. 2014, 4:38-49.
7. Boyerinas B., Park S.M., Hau A., Murmann A.E., Peter M.E. The role of let-7 in cell differentiation and cancer. Endocr. Relat. Cancer 2010, 17:F19-F36.
8. California Institute of Technology, 2012. Treatment of autoimmune inflammation using miR-155. WO/2012/037043.
9. Carrie R.G., Heather M.C., Jennifer J.W., Mary E.W., Lorenzo F.S. Critical analysis of the potential for microRNA biomarkers in breast cancer management. Breast Cancer (Dove Med. Press) 2015, 7:59-79.
10. Charite-Universitatsmedizin Berlin, Technische Universitat Berlin, 2013. MicroRNA target site for cell- or tissue-specific inhibition of expression of a transgene. US 20130281508.
11. Chen Y., Liu W., Chao T., Zhang Y., Yan X., Gong Y., et al. MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G. Cancer Lett. 2008, 272:105-197.
12. Cherie B., Eric A.M. miRNAs in cancer: approaches, aetiology, diagnostics and therapy. Hum. Mol. Genet. 2007, 16:R106-R113.
13. Chieh Y.C., Chang H., David C.C. miR-34 cooperates with p53 in suppression of prostate cancer by joint regulation of stem cell compartment. Cell Rep. 2014, 6:1000-1017.
14. Children's Medical Center Corp., Dana-Farber Cancer Institute, Inc., 2012. Lin28-mediated control of let-7 biogenesis. WO 2012135081.
15. Chung S.S., Hu W., Park C.Y. The role of microRNAs in hematopoietic stem cell and leukemic stem cell function. Ther. Adv. Hematol. 2011, 2:317-334.
16. Cold Spring Harbor Laboratory, University of North California, 2014. Composition and methods for cancer diagnosis utilizing the miR-17-92 cluster. EP 1880027.
17. Council of Scientific and Industrial Research, 2015. Biomarkers useful for detection of types, grades and stages of human breast cancer. US 20150080244.
18. Czyzyk M.F.K., Zhang X. MiR-155 at the heart of oncogenic pathways. Oncogene 2014, 33:677-688.
19. Dharanija M., Katarina C., Burwinkel B., Rongxi Y. Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Front. Genet. 2013, 4:116-127.
20. Elizabeth O.D., Ashish L. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res. 2010, 12:201-211.
21. Febit Holding GmbH, 2012. miRNA in the diagnosis of ovarian cancer. EP 2531611.
22. Flavie S., Marion G., Hubert L., Louis B., Pierre C. Targeting miR-21 for the therapy of pancreatic cancer. Mol. Ther. 2013, 21:986-994.
23. Fujiwara T., Kunisada T., Takeda K. MicroRNAs in soft tissue sarcomas: overview of the accumulating evidence and importance as novel biomarkers. Biomed. Res. Int. 2014, 2014:592868-592877.
24. Fuziwara C.S., Kimura E.T. MicroRNA deregulation in anaplastic thyroid cancer biology. Int. J. Endocrinol. 2014, 2014:743450-743457.
25. Goh J.N., Loo S.Y., Datta A., Siveen K.S., Yap W.N., Cai W., et al. microRNAs in breast cancer: regulatory roles governing the hallmarks of cancer. Biol. Rev. 2015, 2015:1-21.
26. Goljanek-Whysall K., Pais H., Rathjen T., Sweetman D., Dalmay T., Münsterberg A. Regulation of multiple target genes by miR-1 and miR-206 is pivotal for C2C12 myoblast differentiation. J. Cell Sci. 2012, 125:3500-3590.
27. Granados López A.J., López J.A. Multistep model of cervical cancer: participation of miRNAs and coding genes. Int. J. Mol. Sci. 2014, 15:15700-15713.
28. Halkova T., Cuperkova R., Minarik M., Benesova L. MicroRNAs in pancreatic cancer: involvement in carcinogenesis and potential use for diagnosis and prognosis. Gastroenterol. Res. Pract. 2015, 2015. 892903.
29. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010, 17:109-193.
30. Hoffman B., Liebermann D.A. Apoptotic signaling by c-MYC. Oncogene 2008, 27:6462-6472.
31. Hospital Clinic De Barcelona, Centro De Investigacion Biomedica En Red De Enfermedades Hepaticas Y Digestivas, 2013. Plasma microRNAs for the detection of early colorectal cancer. WO 2013093635.
32. Hu, Xiaogu, Immune Disease Inst., Lieberman, Judy, et al., 2008. let-7 microRNA and mimetics thereof as therapeutics for cancer. WO 2008095096.
33. Iorio M.V., Casalini P., Piovan C., Leva G.D., Merlo A., Triulzi T., et al. microRNA-205 regulates HER3 in human breast cancer. Cancer Res. 2009, 69:2100-2195.
34. Italiano A., Thomas R., Breen M., Zhang L., Crago A.M., Singer S., et al. The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification. Genes Chromosomes Cancer 2012, 51:569-578.
35. Jakopovic M., Thomas A., Balasubramaniam S., Schrump D., Giaccone G., Bates S.E. Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy. Front. Oncol. 2013, 3:261.
36. Krishnan S., Kohli S., Rani V. Micro RNAs tiny sequences with enormous potential. Biochem. Biophys. Res. Commun. 2011, 407:445-459.
37. Kwanhian W., Lenze D., Alles J., Motsch N., Barth S., Döll C., et al. MicroRNA-142 is mutated in about 20% of diffuse large B-cell lymphoma. Cancer Med. 2012, 1:141-155.
38. Liao Y.C., Lin T.H., Chen C.Y., Lin S.B., Au L.C. The antileukemia activity of natural product HQ17(3) is possibly associated with downregulation of miR-17-92 cluster. Biomed. Res. Int. 2014, 2014. 306718.
39. Liu C.G., Calin G.A., Volinia S., Croce C.M. MicroRNA expression profiling using microarrays. Nat. Protoc. 2008, 3:563-578.
40. Markou A., Yousef G.M., Stathopoulos E., Georgoulias V., Lianidou E. Prognostic significance of metastasis-related microRNAs in early breast cancer patients with a long follow-up. Clin. Chem. 2014, 60:105-197.
41. Medina P.P., Nolde M., Slack F.J. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010, 467:70-86.
42. MiRNA Therapeutics, Inc., 2010. The Board of Regents of the University of Texas System. Methods and compositions involving mirnas in cancer stem cells. US 20100179213.
43. Mihelich L.B., Maranville J.C., Nolley R., Peehl D.M., Nonn L. Elevated serum microRNA levels associate with absence of high-grade prostate cancer in a retrospective cohort. PLoS One 2015, 10. e0124245-e0124260.
44. Mira Therapeutics, Inc., 2013. Synthetic mimics of miR-34. US 8586727.
45. Monya B. MicroRNA profiling: separating signal from noise. Nat. Methods 2010, 7:687-692.
46. Mostert B., Sieuwerts A.M., Martens J.W.M., Sleijfer S. Diagnostic applications of cell-free and circulating tumor cell-associated mirnas in cancer patients. Expert Rev. Mol. Diagn. 2011, 11:259-275.
47. Niamh L.L., Stephen G.M., John V.R. The role of microRNA in cancer and apoptosis. Biol. Rev. 2009, 84:55-61.
48. Nikitina E.G., Urazova L.N., Stegny V.N. MicroRNAs and human cancer. Exp. Oncol. 2012, 34:2-8.
49. Nobuyoshi K., Haruhisa I., Takahiro O. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010, 101:2087-2092.
50. Pinheiro P.C., Carvalho R.J., Vieira F.Q., Ferreira J.T., Oliveira J., Gonçalves S., et al. MicroRNA-375 plays a dual role in prostate carcinogenesis. Clin. Epidemiol. 2015, 7:42-56.
51. Presneau N., Eskandarpour M., Shemais T., Halai D., Tirabosco R., Flanagan A.M. MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression. Br. J. Cancer 2013, 108:964-972.
52. Qing J., Xinbao H., Min Z., Tang W., Yang M., Li L., et al. microRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 2009, 4:e6816.
53. Ramot At Tel Aviv University, Ltd., 2013. Mir-21 promoter driven targeted cancer therapy. US 20130310446.
54. Ranji N., Sadeghizadeh M., Shokrgozar M.A., Bakhshandeh B., Karimipour M., Amanzadeh A., et al. MiR-17-92 cluster: an apoptosis inducer or proliferation enhancer. Mol. Cell Biochem. 2013, 380:229-238.
55. Regulus Therapeutics Inc., 2015. Alynylam Pharmaceuticals. MicroRNA compositions and methods. US 20150087607.
56. Reneuron Limited, 2015. Stem cell microparticles and miRNA. WO 2015052526.
57. Ribeiro J., Sousa H. MicroRNAs as biomarkers of cervical cancer development: a literature review on miR-125b and miR-34a. Mol. Biol. Rep. 2014, 41:1525-1531.
58. Rosetta Inpharmatics Llc, Cleary, Michele A., Jackson, Aimee L., et al., 2008. Compositions comprising mir34 therapeutic agents for treating cancer. WO2008137867.
59. Ruan K., Fang X., Ouyang G. MicroRNAs novel regulators in the hallmarks of human cancer. Cancer Lett. 2009, 285:116-126.
60. Setoyama T., Ling H., Natsugoe S., Calin G.A. Non-coding RNAs for medical practice in oncology. Keio J. Med. 2011, 60:106-113.
61. Shen J., Todd N.W., Zhang H., Yu L., Lingxiao X., Mei Y., et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab. Invest. 2011, 91:579-587.
62. Shi J.S., Zhang J., Li J. Role of miR-155 in pathogenesis of diffuse large B cell lymphoma and its possible mechanism. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2014, 22:869-872.
63. Stefanie S., Eric A.M., Carlos C. MicroRNA-implications for cancer. Virchows Arch. 2008, 452:1-10.
64. Suzuki H.I., Yamagata K., Sugimoto K., Iwamoto T., Kato S., Miyazono K. Modulation of microRNA processing by p53. Nature 2009, 460:529-543.
65. Thalia A.F., Jessica I.S., Pavel M., Thomas T. miRNAs in human cancer. J. Pathol. 2011, 223:102-115.
66. The Ohio State University Research Foundation, Carlo M.C., 2013. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in mir155 transgenic mice. CA 2650026.
67. The Ohio State University Research Foundation, 2013. MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers. EP 2468898.
68. The Ohio State University, 2013. Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. US 8664192.
69. The University of Pittsburgh-of the commonwealth system of higher education, 2010. Th1-associated micrornas and their use for tumor immunotherapy. US 20100322909.
70. Thomas Jefferson University, 2013. Compositions and methods for cancer diagnosis and therapy. US 8557515.
71. Thomas Jefferson University, 2013. Compositions and methods for cancer diagnosis and therapy. US 8557515.
72. Thomas Jefferson University, 2013. Diagnosis and treatment of cancers with microRNA located in or near cancer-associated chromosomal features. US 13/972759.
73. Tili E., Croce C.M., Michaille J.J. miR-155: on the crosstalk between inflammation and cancer. Int. Rev. Immunol. 2009, 28:264-274.
74. Vecchione A., Croce C.M. Apoptomirs small molecules have gained the license to kill. Endocr. Relat. Cancer 2010, 17:F37-F50.
75. Verena S., Samantha P., Alexander D., Hui L., Armin G., Martin P. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer. World J. Gastroenterol. 2014, 20:11727-11735.
76. Veridex Llc, Raponi, Mitch, Dossey, Lesley Estelle, 2009. Process for predicting the prognosis of squamous cell lung cancer. WO 2009059016.
77. Wang R.J., Zheng Y.H., Wang P., Zhang J.Z. Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer. Int. J. Clin. Exp. Pathol. 2015, 8:765-771.
78. Wen T.W., Yue Q.C. Circulating miRNAs in cancer: from detection to therapy. J. Hematol. Oncol. 2014, 7:86-95.
79. Whitney, D.H., Allegro diagnostics Corp., Jun L., 2015. Methods and compositions for detecting cancer based on miRNA expression profiles, US 20150080243.
80. Wozniak M.B., Scelo G., Muller D.C., Mukeria A., Zaridze D., Brennan P. Circulating MicroRNAs as non-invasive biomarkers for early detection of non-small-cell lung cancer. PLoS One 2015, 10:e0125026.
81. Wu W. MicroRNAs patents: the road from bench to bedsides for cancer treatment. Recent Pat. DNA Gene Sequences 2011, 5:86-91.
82. Xiangyang X., Jun S., Qingfeng Z., Zhangxun W., Yufu H., Weiqing P. Identification and characterization of novel microRNAs from Schistosomajaponicum. PLoS One 2008, 3:e4034-e4043.
83. Yale University, 2013. Genetic Lesion Associated With Cancer. US 20130089862.
84. Zhang B., Wang Q., Pan X. MicroRNAs and their regulatory roles in animals and plants. J. Cell Physiol. 2007, 210:279-289.
85. Zhang Z., Liu Z., Ren W., Ye X., Zhang Y. The miR-200 family regulates the epithelial-mesenchymal transition induced by EGF/EGFR in anaplastic thyroid cancer cells. Int. J. Mol. Med. 2012, 30:856-862.
86. Zhang Y., Wang Z., Gemeinhart R.A. Progress in microRNA delivery. J. Control Release 2013, 172:962-974.
87. Zhang Z.L., Bai Z.B., Wang X., Bai L., Miao F., Pei H.H. miR-186 and 326 predict the prognosis of pancreatic ductal adenocarcinoma and affect the proliferation and migration of cancer cells. PLoS One 2015, 10:e0118814.
88. Zhiguo W., Xioabin L., Yanjie L., Baofeng Y. miRNAs at the heart of the matter. J. Mol. Med. 2008, 86:771-783.
89. Zhou J., Tian Y., Li J., Lu B., Sun M., Zou Y., et al. miR-206 is down-regulated in breast cancer and inhibits cell proliferation through the up-regulation of cyclinD2. Biochem. Biophys. Res. Commun. 2013, 433:207-222.